Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Humira Biosimilar Market Report. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


Humira Biosimilar Trends and Forecast

The future of the global humira biosimilar market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global humira biosimilar market is expected to grow with a CAGR of 26.0% from 2024 to 2030. The major drivers for this market are growing prevalence of autoimmune diseases, rising pharmaceutical firms to develop and commercialize biosimilar versions of humira, and biosimilars provide a more affordable alternative to the reference biologic medicine.
Humira Biosimilar Trends and Forecast

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Humira Biosimilar by Segment

Humira Biosimilar by Segment

The study includes a forecast for the global humira biosimilar by product type, patient age, indication, distribution channel, and region.

Humira Biosimilar Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:


• Biosimilar Humira (Adalimumab)
• Interchangeable Biosimilar Humira

Humira Biosimilar Market by Patient Age [Shipment Analysis by Value from 2018 to 2030]:


• Adult Patients
• Pediatric Patients
• Geriatric Patients

Humira Biosimilar Market by Indication [Shipment Analysis by Value from 2018 to 2030]:


• Rheumatoid Arthritis
• Psoriasis
• CrohnÄX%$%XS Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Others

Humira Biosimilar Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:


• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Humira Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:


• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Humira Biosimilar Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies humira biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the humira biosimilar companies profiled in this report include-
• Amgen
• Samsung Bioepis
• Sandoz International
• Mylan
• Boehringer Ingelheim International
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Biogen
• AbbVie

Humira Biosimilar Market Insights

Lucintel forecasts that biosimilar humira (adalimumab) will remain the larger segment over the forecast period.
Within this market, hospital pharmacy will remain the largest segment.
North America will remain the largest region over the forecast period due to the expiration of humiraÄX%$%Xs patents, the market for biosimilars is projected to expand in the region.

Features of the Global Humira Biosimilar Market

Market Size Estimates: Humira biosimilar market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Humira biosimilar market size by product type, patient age, indication, distribution channel, and region in terms of value ($B).
Regional Analysis: Humira biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product type, patient age, indication, distribution channel, and regions for the humira biosimilar market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the humira biosimilar market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for humira biosimilar market?
Answer: The global humira biosimilar market is expected to grow with a CAGR of 26.0% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the humira biosimilar market?
Answer: The major drivers for this market are growing prevalence of autoimmune diseases, rising pharmaceutical firms to develop and commercialize biosimilar versions of humira, and biosimilars provide a more affordable alternative to the reference biologic medicine.
Q3. What are the major segments for humira biosimilar market?
Answer: The future of the global humira biosimilar market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.
Q4. Who are the key humira biosimilar market companies?
Answer: Some of the key humira biosimilar companies are as follows:
• Amgen
• Samsung Bioepis
• Sandoz International
• Mylan
• Boehringer Ingelheim International
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Biogen
• AbbVie
Q5. Which humira biosimilar market segment will be the largest in future?
Answer: Lucintel forecasts that biosimilar humira (adalimumab) will remain the larger segment over the forecast period.
Q6. In humira biosimilar market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the expiration of humiraÄX%$%Xs patents, the market for biosimilars is projected to expand in the region.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the humira biosimilar market by product type (biosimilar humira (adalimumab) and interchangeable biosimilar humira), patient age (adult patients, pediatric patients, and geriatric patients), indication (rheumatoid arthritis, psoriasis, crohnÄX%$%Xs disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and others), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

For any questions related to Humira Biosimilar Market, Humira Biosimilar Market Size, Humira Biosimilar Market Growth, Humira Biosimilar Market Analysis, Humira Biosimilar Market Report, Humira Biosimilar Market Share, Humira Biosimilar Market Trends, Humira Biosimilar Market Forecast, Humira Biosimilar Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents

1. Executive Summary
2. Global Humira Biosimilar Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Humira Biosimilar Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Humira Biosimilar Market by Product Type
3.3.1: Biosimilar Humira (Adalimumab)
3.3.2: Interchangeable Biosimilar Humira
3.4: Global Humira Biosimilar Market by Patient Age
3.4.1: Adult Patients
3.4.2: Pediatric Patients
3.4.3: Geriatric Patients
3.5: Global Humira Biosimilar Market by Indication
3.5.1: Rheumatoid Arthritis
3.5.2: Psoriasis
3.5.3: CrohnÄX%$%Xs Disease
3.5.4: Ulcerative Colitis
3.5.5: Ankylosing Spondylitis
3.5.6: Juvenile Idiopathic Arthritis
3.5.7: Others
3.6: Global Humira Biosimilar Market by Distribution Channel
3.6.1: Hospital Pharmacies
3.6.2: Retail Pharmacies
3.6.3: Online Pharmacies
3.6.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Humira Biosimilar Market by Region
4.2: North American Humira Biosimilar Market
4.2.1: North American Humira Biosimilar Market by Product Type: Biosimilar Humira (Adalimumab) and Interchangeable Biosimilar Humira
4.2.2: North American Humira Biosimilar Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others
4.3: European Humira Biosimilar Market
4.3.1: European Humira Biosimilar Market by Product Type: Biosimilar Humira (Adalimumab) and Interchangeable Biosimilar Humira
4.3.2: European Humira Biosimilar Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others
4.4: APAC Humira Biosimilar Market
4.4.1: APAC Humira Biosimilar Market by Product Type: Biosimilar Humira (Adalimumab) and Interchangeable Biosimilar Humira
4.4.2: APAC Humira Biosimilar Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others
4.5: ROW Humira Biosimilar Market
4.5.1: ROW Humira Biosimilar Market by Product Type: Biosimilar Humira (Adalimumab) and Interchangeable Biosimilar Humira
4.5.2: ROW Humira Biosimilar Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Humira Biosimilar Market by Product Type
6.1.2: Growth Opportunities for the Global Humira Biosimilar Market by Patient Age
6.1.3: Growth Opportunities for the Global Humira Biosimilar Market by Indication
6.1.4: Growth Opportunities for the Global Humira Biosimilar Market by Distribution Channel
6.1.5: Growth Opportunities for the Global Humira Biosimilar Market by Region
6.2: Emerging Trends in the Global Humira Biosimilar Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Humira Biosimilar Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Humira Biosimilar Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Amgen
7.2: Samsung Bioepis
7.3: Sandoz International
7.4: Mylan
7.5: Boehringer Ingelheim International
7.6: Pfizer
7.7: Fresenius Kabi
7.8: Coherus BioSciences
7.9: Biogen
7.10: AbbVie
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Humira Biosimilar Market Report: Trends, Forecast and Competitive Analysis to 2030 Full Report $ 4,850
A 150 Page Report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.